Loading patent…
AssigneeThe Regents of the University of Michigan
InventorRonald Buckanovich
Estimating the term…
The present invention determined that EGFL6 functions as a tumor vascular regulator of ovarian cancer stem cells (CSC). In addition, the present invention determined that a novel EGFL6 blocking antibody was able to restrict cancer cell growth and delay disease recurrence. As such, the present invention provides compositions and methods for inhibiting cancer cell growth, proliferation and/or metastasis. In particular, the present invention provides methods for inhibiting cancer cell growth, proliferation and/or metastasis through administration of a composition comprising an agent capable of inhibiting the function of EGFL6 (e.g., thereby inhibiting related cancer cell growth). In some embodiments, the agent capable of inhibiting the function of EGFL6 is an EGFL6 blocking antibody. The agents and related compositions additionally find use in diagnostic and research settings.
A method for inhibiting cancer cell proliferation, metastases and/or growth comprising providing a sample comprising cancer cells expressing EGFL6 and exposing said sample to a composition comprising an agent capable of inhibiting EGFL6 function, wherein said agent is an EGFL6 blocking antibody directed against a peptide consisting of the following amino acid sequence:
A composition comprising an antibody directed against an EGFL6 peptide, wherein said antibody is directed against the following amino acid sequence:
A method for treating a subject suffering from a disorder affected by EGFL6 activity, comprising administering to the subject a composition comprising an agent capable of inhibiting EGFL6 function, wherein said agent is an EGFL6 blocking antibody directed against a peptide consisting of the following amino acid sequence:
Dependencies are inferred from the claim text.